Verastem Inc
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: -
VSTM
Verastem Inc
GICS: -
·
Sektor: Biopharmaceuticals
·
Sub-Sektor: -
NAME
Verastem Inc
ISIN
US92337C1045
TICKER
VSTM
MIC
XNAS
REUTERS
VSTM.OQ
BLOOMBERG
VSTM US
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Mi., 06.11.2024
Verastem
US92337C1045
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the third quarter ended September 30, 2024.
“In the third quarter of 2024, we made advancements in our recurrent low-grade serous ovarian cancer program, i...
Verastem
Do., 31.10.2024
Verastem
US92337C1045
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company has completed its rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the investigational and potential first-in-class combination of avutometinib, an oral R...
Verastem
Do., 31.10.2024
Verastem
US92337C1045
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in the following upcoming investor conferences:
2024 Truist Securities BioPharma Symposium on November 7, 2024
Guggenheim Healthcare Innovation Conference; firesi...
Verastem
Do., 17.10.2024
Verastem
US92337C1045
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced updated data from the Phase 2 RAMP 201 (ENGOTov60/GOG3052) clinical trial evaluating the combination of avutometinib, an oral RAF/MEK clamp, and defactinib, an oral, selective FAK inhibitor, in patients with ...
Verastem
Mi., 09.10.2024
Verastem
US92337C1045
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced further details for its late-breaking presentation of mature data from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/GOG-3052) clinical trial to be presented as an oral presentation at a plenary session at the Int...
Verastem
Mo., 07.10.2024
Verastem
US92337C1045
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 109,000 shares of its common stock to nine new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the empl...
Verastem
Di., 10.09.2024
Verastem
US92337C1045
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18 at 3:40 pm EDT.
A live webcast of the fireside chat can be accessed und...
Verastem
Di., 10.09.2024
Verastem
US92337C1045
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the acceptance of a late-breaking abstract of the mature data from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/GOG-3052) clinical trial to be presented as an oral presentation at a plenary session at the Interna...
Verastem
Di., 03.09.2024
Verastem
US92337C1045
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, and the STAAR Ovarian Cancer Foundation today announced the first Low-Grade Serous Ovarian Cancer Awareness Day or “LGSOC Awareness Day” on September 9, 2024.
This press release features multimedia. View the full release he...
Verastem
Do., 08.08.2024
Verastem
US92337C1045
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the second quarter ended June 30, 2024.
“We have made tremendous progress in the second quarter as we initiated our rolling NDA submission for avutometini...
Verastem
Informationen zu Product Placements
